Format

Send to

Choose Destination
Am J Reprod Immunol. 2013 Oct;70(4):299-308. doi: 10.1111/aji.12130. Epub 2013 May 7.

Antiphospholipid antibodies affect human endometrial angiogenesis: protective effect of a synthetic peptide (TIFI) mimicking the phospholipid binding site of β(2) glycoprotein I.

Author information

1
Department of Obstetrics and Gynecology, Università Cattolica del Sacro Cuore, Rome, Italy.

Abstract

PROBLEM:

Aim of our study was to investigate whether TIFI, a syntetic peptide able to compete with anti-phospholipid antibodies (aPL) in the binding to endothelium, may restore aPL-inhibited endometrial angiogenesis.

METHODS:

The protective role of TIFI was evaluated on: i) aPL-inhibited of human endometrial endothelial cells (HEEC) angiogenesis in vitro; ii) aPL-inhibited vascular endothelial growth factor (VEGF) and metalloproteases (MMPs) expression; iii) aPL-inhibited Nuclear Factor-κB (NF-κB) and Extracellular signal-Regulated Kinase (ERK) activation and (iv) angiogenesis in vivo.

RESULTS:

TIFI restores in a dose-dependent manner: i) aPL-mediated inhibition of HEEC angiogenesis in vitro and in vivo (P < 0.05), ii) VEGF (P < 0.001) and MMP-2 (P < 0.05) expression and iii) NF-κB DNA binding and ERK-1/2 activation (P < 0.05) inhibited by aPL.

CONCLUSION:

Our results show for the first time the protective effects of TIFI, as represented by its ability to interfere with aPL mediated anti-angiogenic activity.

KEYWORDS:

Antiphospholipid antibodies; TIFL; endometrial angiogenesis

PMID:
23650919
DOI:
10.1111/aji.12130
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center